secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0001104659-25-011851
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune Q3 net loss $66.3M; FDA accepts RP1 BLA with priority review, PDUFA July 22
--------------------------------------------------------------------------------

- FDA accepted BLA for RP1+nivolumab in advanced melanoma with Priority Review; PDUFA date July 22, 2025.
- Net loss $66.3M for fiscal Q3 2025, up from $51.1M in Q3 2024; R&D expense $48.0M.
- Cash & investments $536.5M as of Dec 31, 2024, expected to fund operations into Q4 2026.
- Public offering raised ~$156M net to support RPx development and potential commercial launch.
- First patients enrolled in RP2 registration-directed trial for uveal melanoma and Phase 2 HCC trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465925011851/0001104659-25-011851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465925011851/tm256243d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-011851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer